Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ChronoMag Smart Tablet is a magnesium-based oral formulation developed by Laboratoires Mayoly Spindler. It utilizes a proprietary "Smart Tablet" technology designed to provide a controlled release of magnesium, thereby optimizing its bioavailability and potentially minimizing the gastrointestinal side effects often associated with standard magnesium supplementation. The formulation was evaluated in clinical studies, such as the Phase 1 trial NCT01935570, which compared the pharmacokinetic profile of a 50 mg ChronoMag dose against a 100 mg dose of the standard magnesium supplement Mag2 (magnesium pidolate) in healthy volunteers. Magnesium is an essential mineral and electrolyte that serves as a vital cofactor for over 300 enzymatic reactions, including those involved in energy metabolism, protein synthesis, muscle contraction, and nerve impulse conduction.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on magnesium (Mayoly Spindler).